Patent · US Active

Polypeptides

US10562955B2 · kind B2 · utility

0Cited by

6References

47Claims

0Family size

Assignee

AFFIBODY AB · SE

Inventors

Caroline Ekblad · Boo, SE
Elin Gunneriusson · Hallsberg, SE
Malin Lindborg · Boo, SE
Lars Abrahmsen · Bromma, SE
John Löfblom · Huddinge, SE
Torbjörn Gräslund · Åtvidaberg, SE
Johan Seijsing · Stockholm, SE

Key dates

Filing date	Dec 14, 2017
Grant date	Feb 18, 2020
Priority date	—
Expiry date	Dec 14, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/74
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29. The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.